AllianzIM U.S. Large Cap 6 Month Buffer10 Jun/Dec ETF (SIXD)
Live price chart, market sentiment, and community perspectives for AllianzIM U.S. Large Cap 6 Month Buffer10 Jun/Dec ETF (CBOE: SIXD).
Live price chart, market sentiment, and community perspectives for AllianzIM U.S. Large Cap 6 Month Buffer10 Jun/Dec ETF (CBOE: SIXD).
On our options desk, we are keeping a close watch on SIXD's underlying SPY options structures, particularly given that the current outcome period spanning June 1, 2026 to November 30, 2026 incorporates specific call and put positions like the SPY 11/30/2026 5.60 C and 756.40 P strikes. The 0.74% expense ratio is a standard frictional cost for this type of defined-outcome wrapper.
When evaluating structured ETFs like SIXD during client portfolio reviews, I always emphasize that the starting cap (Gross/Net at 8.08% / 7.70% for the current period) and the starting buffer (10% / 9.62%) are locked in at the start of the outcome period. Clients must understand that buying midway through a 6-month cycle alters the effective risk-reward profile significantly.
From a market sentiment perspective, Danelfin's AI model currently assigns SIXD a 'Hold' rating with a 5/10 score, indicating a 62% probability of outperforming the broader ETF universe over the next 3 months. Investors looking for a downside hedge are classifying this under downside protection strategies (#255 of 302 in Downside Hedge), though it is hardly a aggressive growth play.
Reviewing the V-Lab Spline-GARCH volatility analysis for SIXD, the short-run volatility forecasts show a 1-day prediction around 8.13% with a half-life of 2 trading days. Because the model fits a time-varying baseline, volatility tends to mean-revert toward a slowly shifting long-run level, which fits nicely into our quantitative risk management parameters.
As a risk manager, I track the name change from the AllianzIM U.S. Large Cap 6 Month Buffer10 Jun/Dec ETF to the AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETF as noted in the May/June 2026 supplement. Trading volume around 32.3K shares and prices hovering near $31.37 show stable, predictable liquidity on the Cboe BZX exchange for institutional participants.
Explore plasma cleansing, somatic organ swaps, and BCI.